Cancer Research and Treatment

Original Articles

Breast cancer

Secondary Cancer Risk in Breast Cancer with and without Radiotherapy: The Observational Health Data Sciences and Informatics (OHDSI) Cohort Study: Seok Kim, Dachung Boo, Sooyoung Yoo, Borham Kim, Kyubo Kim, Kwangsoo Kim, Eunhye Song, Junmo Kim, Hyun Gee Ryoo, Jin Chul Paeng, In Young Choi, SooJeong Ko, Ie Ryung Yoo, Rae Woong Park, Ho-Young Lee; Cancer Res Treat. 2026;58(2):481-491. Published online June 5, 2025; DOI: https://doi.org/10.4143/crt.2024.968

Abstract PDF Supplementary Material PubReader ePub: Purpose
Radiotherapy is used to reduce the risk of breast cancer recurrence after surgery, but it is a potential cause of secondary cancer. We validated the risk of secondary cancer in primary breast cancer who received radiotherapy compared with those who did not from a matched cohort using a large-scale observational study of the Observational Health Data Sciences and Informatics (OHDSI) data network.
Materials and Methods
A retrospective comparative cohort study using propensity score-matched cohorts was performed using two Observational Medical Outcome Partnership common data model databases, from tertiary general hospitals in South Korea. Among female patients who underwent surgery after the diagnosis of breast cancer, the risk of secondary primary malignant occurrence after 1:1 matching was analyzed.
Results
Among 27,078 patients with breast cancer, there was no significant difference in the risk of secondary cancer following radiotherapy in 4,426 patients after 1:1 propensity-score matching. Further, there were no significant differences in the sensitivity analysis according to age, latency period, and number of radiation treatments.
Conclusion
There was no difference in the risk of secondary cancer in the patients diagnosed with breast cancer depending on whether or not radiotherapy was performed after surgery. In the future, it is necessary to analyze including data generated during cancer treatment.

3,566 View
96 Download

SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer: Yoo-Kang Kwak, Hee Hyun Park, Kyu Hye Choi, Eun Young Park, Soo Yoon Sung, Sea-Won Lee, Ji Hyun Hong, Hyo Chun Lee, Ie Ryung Yoo, Yeon Sil Kim; Cancer Res Treat. 2020;52(1):85-97. Published online May 17, 2019; DOI: https://doi.org/10.4143/crt.2019.007

Abstract PDF PubReader ePub

Purpose
Fluorodeoxyglucose positron emission tomography–computed tomography (PET-CT) is gaining evidence as a predictive factor in non-small cell lung cancer (NSCLC). Stereotactic ablative radiotherapy (SABR) is the standard treatment in early-stage NSCLC when a patient is unsuitable for surgery. We performed a study to assess the prognostic clinical significance of PET-CT after SABR in early-stage NSCLC.
Materials and Methods
Seventy-six patients with stage I NSCLC treated with SABR were investigated. Total radiation dose ranged from 36 to 63 Gy in three to eight fractions depending on tumor location and size. Respiratory motion control was implemented at simulation and during treatment. PET-CT prior to SABR was performed in 66 patients (86.8%).
Results
Median follow-up time was 32 months (range, 5 to 142 months). Local control rate at 1, 2, and 5 years were 95.9%, 92.8%, and 86.7%, respectively. Overall survival (OS) at 1, 2, and 5 years were 91.0%, 71.3%, and 52.1% respectively. Cause-specific survival at 1, 2, and 5 years were 98.6%, 93.1%, and 84.3% respectively. Tumor size and pre-SABR maximal standardized uptake value (SUVmax) demonstrated statistical significance in the Kaplan-Meier survival analyses with log-rank test. In multivariate analyses pre-SABR SUVmax remained statistically significant in correlation to OS (p=0.024; hazard ratio [HR], 3.2; 95% confidence interval [CI], 1.2 to 8.8) and with marginal significance in regards to regional progression-free survival (p=0.059; HR, 32.5; 95% CI, 2.6 to 402.5).
Conclusion
Pre-SABR SUVmax demonstrated a predictive power in statistical analyses. Tumors with SUVmax above 6 at diagnosis were associated with inferior outcomes.

Citations

Citations to this article as recorded by

Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer
Yupeng Di, Haifeng Pang, Xuan Wang, Lingling Meng
Clinical Lung Cancer.2026; 27(6): 75. CrossRef
Enhanced NSCLC subtyping and staging through attention-augmented multi-task deep learning: A novel diagnostic tool
Runhuang Yang, Weiming Li, Siqi Yu, Zhiyuan Wu, Haiping Zhang, Xiangtong Liu, Lixin Tao, Xia Li, Jian Huang, Xiuhua Guo
International Journal of Medical Informatics.2025; 193: 105694. CrossRef
The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients
Maria Fala, Eleni Josephides, Sweni Shah, Hemal Ariyaratne, Anant Patel, Gary J. R. Cook, Sugama Chicklore, Thomas Wagner
European Journal of Nuclear Medicine and Molecular Imaging.2025; 53(1): 181. CrossRef
Quantitative Imaging Biomarkers in Lung Cancer: Current Trends and Future Directions
Joice Prodigios, Ronak Kundalia, Amanda Acevedo, Jean Bontemps, David Pfaehler, Md Mahfuz Al Hasan, Kyle B. See, Nupur Verma, Daniela Hochhegger, Alysson Roncally Silva Carvalho, Tan-Lucien Mohammed, Bruno Hochhegger
Seminars in Roentgenology.2025; 60(4): 439. CrossRef
Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer – Results from a Single Institution Study
Benjamin George, Atallah Baydoun, Samar Bhat, Lauryn Bailey, Theodore Arsenault, Yilun Sun, Yuxia Zhang, Yiran Zheng, Prashant Vempati, Tarun Podder, Tithi Biswas
Clinical Lung Cancer.2024; 25(4): e181. CrossRef
Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis
Yongming Wu, Wenpeng Song, Denian Wang, Junke Chang, Yan Wang, Jie Tian, Sicheng Zhou, Yingxian Dong, Jing Zhou, Jue Li, Ziyi Zhao, Guowei Che
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer
Pengfei Zhang, Wei Chen, Kewei Zhao, Xiaowen Qiu, Tao Li, Xingzhuang Zhu, Peng Sun, Chunsheng Wang, Yipeng Song
BMC Medical Imaging.2023;[Epub] CrossRef
Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors
Jixia Han, Qi Song, Feng Guo, Rui Du, Henghu Fang, Jingbo Kang, Zejun Lu
Nuclear Medicine Communications.2022; 43(6): 717. CrossRef
Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer
Yu-Sen Huang, Jenny Ling-Yu Chen, Hsin-Ming Chen, Li-Hao Yeh, Jin-Yuan Shih, Ruoh-Fang Yen, Yeun-Chung Chang
BMC Cancer.2021;[Epub] CrossRef
Potential role of functional imaging in predicting outcome for patients treated with carbon ion therapy: a review
Giulia Riva, Sara Imparato, Giovanni Savietto, Mattia Pecorilla, Alberto Iannalfi, Amelia Barcellini, Sara Ronchi, Maria Rosaria Fiore, Chiara Paganelli, Giulia Buizza, Mario Ciocca, Guido Baroni, Lorenzo Preda, Ester Orlandi
The British Journal of Radiology.2021;[Epub] CrossRef
Prognostic value of metabolic signature on 18F-FDG uptake in breast cancer patients after radiotherapy
Jin Meng, Emmanuel Deshayes, Li Zhang, Wei Shi, Xiaomeng Zhang, Xingxing Chen, Xin Mei, Jinli Ma, Yizhou Jiang, Jiong Wu, Zhimin Shao, Xiaoli Yu, Zhaozhi Yang, Xiaomao Guo
Molecular Therapy Oncolytics.2021; 23: 412. CrossRef
Parámetros cuantitativos de la PET/TC con 18F-FDG como factores pronósticos en el cáncer de pulmón localizado e inoperable
J.R. Infante, J. Cabrera, J.I. Rayo, C. Cruz, J. Serrano, M. Moreno, A. Martínez, P. Jiménez, A. Cobo
Revista Española de Medicina Nuclear e Imagen Molecular.2020; 39(6): 353. CrossRef
18F-FDG PET/CT quantitative parameters as prognostic factors in localized and inoperable lung cancer
J.R. Infante, J. Cabrera, J.I. Rayo, C. Cruz, J. Serrano, M Moreno, A. Martínez, P. Jiménez, A. Cobo
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2020; 39(6): 353. CrossRef

10,351 View
135 Download
12 Web of Science
13 Crossref

Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer: Mi Joo Chung, Yeon Sil Kim, Ji Yoon Kim, Yun Hee Lee, Ji Hyun Jang, Jin Hyoung Kang, Ie Ryung Yoo, Youn Soo Lee; Cancer Res Treat. 2016;48(4):1167-1176. Published online March 3, 2016; DOI: https://doi.org/10.4143/crt.2015.379

Abstract PDF PubReader ePub

Purpose
We investigated the prognostic factors for distant metastasis (DM) in patients with locally advanced oropharyngeal cancer (OPC) treated with surgery and adjuvant radiotherapy with or without concurrent chemotherapy.
Materials and Methods
Eighty-five patients treated between January 1995 and August 2014 were evaluated retrospectively. Data regarding the pathological tumour and nodal status, human papillomavirus (HPV) status, treatment characteristics, and pretreatment maximum standardized uptake value (SUVmax) of 18-fluoro-2-deoxyglucose positron emission tomography–computed tomography scan (¹⁸F-FDG PET-CT) were evaluated, and their influence on DM and survival outcomes were analyzed.
Results
Median follow-up period was 48.0 months. Recurrence was observed in 20 patients, including locoregional recurrence and DM. DM was observed in 13 patients. A multivariate analysis confirmed that the presence of lymphovascular invasion (p=0.031), lower neck lymph node (LN) involvement (p=0.006), SUVmax ≥ 9.7 (p=0.014), and tumour size ≥ 3 cm (p=0.037) significantly affected DM. HPV status was not associated with DM. Perineural invasion (p=0.048), lower neck LNinvolvement (p=0.008), SUVmax ≥ 9.7 (p=0.019), and tumour size ≥ 3 cm (p=0.033) were also significant factors for the DM-free survival rate.
Conclusion
Lower neck LN involvement, high SUVmax in pretreatment ¹⁸F-FDG PET-CT, and large tumour size were predictive factors for DM in patients of OPC.

Citations

Citations to this article as recorded by

Perineural Invasion Affects the Risk and Pattern of Recurrence in Non-Small Cell Lung Cancer
Beatrice Chia-Hui Shih, Woohyun Jung, Jeong Hoon Lee, Jae Hyun Jeon, Sukki Cho, Jin-Haeng Chung, Kwhanmien Kim, Sanghoon Jheon
European Journal of Cardio-Thoracic Surgery.2025;[Epub] CrossRef
An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375)
Jinlong Wei, Jing Su, Jianfeng Wang, Xiaojing Jia, Qin Zhao, Weiyan Shi, Huanhuan Wang, Zhuangzhuang Zheng, Xin Jiang
Head & Neck.2024; 46(4): 915. CrossRef
The Prognostic Role of Perineural Invasion for Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Zhuo-Ying Tao, Guang Chu, Yu-Xiong Su
Cancers.2024; 16(14): 2514. CrossRef
Management of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma: a Contemporary Review
Sam Dowthwaite, James Jackson, Marcin Dzienis, Eric Khoo, Mathew Cronin, Emily Guazzo
Current Oncology Reports.2023; 25(5): 501. CrossRef
A Mn-doped calcium phosphate nanoparticle-based multifunctional nanocarrier for targeted drug delivery and cellular MR imaging
Chaohui Zhou, Shenglei Hou, Chusen Huang, Nengqin Jia
Journal of Nanoparticle Research.2022;[Epub] CrossRef
Importance of lymph node ratio in HPV-related oropharyngeal cancer patients treated with surgery and adjuvant treatment
Kyu Hye Choi, Jin Ho Song, Ji Hyun Hong, Youn Soo Lee, Jin Hyoung Kang, Dong-Il Sun, Min-Sik Kim, Yeon-Sil Kim, Yifei Wang
PLOS ONE.2022; 17(8): e0273059. CrossRef
18F-FDG PET/CT–Based Prognostic Survival Model After Surgery for Head and Neck Cancer
Gwenaelle Creff, Franck Jegoux, Xavier Palard, Adrien Depeursinge, Ronan Abgral, Remi Marianowski, Jean-Christophe Leclere, Thomas Eugene, Olivier Malard, Renaud De Crevoisier, Anne Devillers, Joel Castelli
Journal of Nuclear Medicine.2022; 63(9): 1378. CrossRef
Risk stratification of postoperative recurrence in hypopharyngeal squamous-cell carcinoma patients with nodal metastasis
Hanqing Lin, Tian Wang, Yu Heng, Xiaoke Zhu, Liang Zhou, Ming Zhang, Yong Shi, Pengyu Cao, Lei Tao
Journal of Cancer Research and Clinical Oncology.2021; 147(3): 803. CrossRef
A two-fold interpenetration pillar-layered metal-organic frameworks based on BODIPY for chemo-photodynamic therapy
Yang Meng, Yingying Du, Yanxin Lin, Yu Su, Ruonan Li, Yaqing Feng, Shuxian Meng
Dyes and Pigments.2021; 188: 109174. CrossRef
Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia
Chichao Xia, Sile Li, Teng Long, Zigui Chen, Paul K. S. Chan, Siaw Shi Boon
Cancers.2021; 13(11): 2691. CrossRef
Evaluation of the Prognostic Value of FDG PET/CT Parameters for Patients With Surgically Treated Head and Neck Cancer
Gwenaelle Creff, Anne Devillers, Adrien Depeursinge, Xavier Palard-Novello, Oscar Acosta, Franck Jegoux, Joel Castelli
JAMA Otolaryngology–Head & Neck Surgery.2020; 146(5): 471. CrossRef
Sequentially self-assembled polysaccharide-based nanocomplexes for combined chemotherapy and photodynamic therapy of breast cancer
Yaping Wang, Ming Yang, Junmin Qian, Weijun Xu, Jinlei Wang, Guanghui Hou, Lijie Ji, Aili Suo
Carbohydrate Polymers.2019; 203: 203. CrossRef
Self-assembly of photosensitive and chemotherapeutic drugs for combined photodynamic-chemo cancer therapy with real-time tracing property
Shengtao Wang, Jingtao Li, Zhou Ye, Jieling Li, Anhe Wang, Jing Hu, Shuo Bai, Jian Yin
Colloids and Surfaces A: Physicochemical and Engineering Aspects.2019; 574: 44. CrossRef
Patterns of recurrence in oral tongue cancer with perineural invasion
Jennifer R. Cracchiolo, Bin Xu, Jocelyn C. Migliacci, Nora Katabi, David G. Pfister, Nancy Y. Lee, Snehal G. Patel, Ronald A. Ghossein, Richard J. Wong
Head & Neck.2018; 40(6): 1287. CrossRef
Targeted Chemo-Photodynamic Combination Platform Based on the DOX Prodrug Nanoparticles for Enhanced Cancer Therapy
Yumin Zhang, Fan Huang, Chunhua Ren, Lijun Yang, Jianfeng Liu, Zhen Cheng, Liping Chu, Jinjian Liu
ACS Applied Materials & Interfaces.2017; 9(15): 13016. CrossRef

13,702 View
223 Download
11 Web of Science
15 Crossref

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis: Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang; Cancer Res Treat. 2016;48(3):1110-1119. Published online January 6, 2016; DOI: https://doi.org/10.4143/crt.2015.289

Abstract PDF PubReader ePub

Purpose
The aim of this study was to analyze clinical characteristics of skeletal metastasis in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) and treatment outcomes of continued EGFR tyrosine kinase inhibitor (TKI) therapy in patients presenting with skeletal metastasis progression. Materials and Methods Of the 216 patients treated with EGFR-TKI for management of stage III-IV NSCLC between 2006 and 2012 in Seoul St. Mary’s Hospital, 76 patients with confirmed EGFR-mutated NSCLC with skeletal metastases during therapy were analyzed retrospectively.
Results
Of 76 patients with EGFR mutant lung cancer with skeletal metastasis, 37 patients developed first progressive disease (PD) in skeletal regions. EGFR-TKI was continued in these 37 patients after first PD in skeletal regions. Median time to first PD of skeletal regions was 8.9 months (95% confidence interval [CI], 4.8 to 13.0). Median time of continued EGFR-TKI after first PD of skeletal regions was 8.0 months (95% CI, 2.9 to 13.0) in patients with disease progression of preexisting regions, 5.6 months (95% CI, 4.5 to 6.7) in patients showing new localized regions, and 3.3 months (95% CI, 1.1 to 5.5) in patients with multiple new metastatic regions (p=0.006). Median time of postskeletal metastasis progression survival was 23.0 months (95% CI, 13.5 to 32.5), 15.0 months (95% CI, 3 to 34.7), and 7.0 months (95% CI, 6.0 to 8.0) (p=0.004) in the above described patient groups, respectively. Overall, seven patients (18.9%) had more than one episode of skeletal progression of disease without extraskeletal PD. Conclusion Continued EGFR-TKI treatment with adequate local treatment after progression of skeletal metastasis may be considered for patients who show disease progression in preexisting regions or local progression.

Citations

Citations to this article as recorded by

From Tumor to Bone: Growth Factor Receptors as Key Players in Cancer Metastasis
Khalid Said Mohammad, Shahid Akhtar Akhund
Frontiers in Bioscience-Landmark.2024;[Epub] CrossRef
Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
Yue-Yun Chen, Pei-Pei Wang, Yang- Fu, Qing- Li, Jiang-Fang Tian, Ting- Liu, Zhen Lin, Zhen-Yu Ding
Journal of Bone Oncology.2021; 29: 100369. CrossRef
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value
Xupeng Chai, Eloy Yinwang, Zenan Wang, Zhan Wang, Yucheng Xue, Binghao Li, Hao Zhou, Wenkan Zhang, Shengdong Wang, Yongxing Zhang, Hengyuan Li, Haochen Mou, Lingling Sun, Hao Qu, Fangqian Wang, Zengjie Zhang, Tao Chen, Zhaoming Ye
Frontiers in Oncology.2021;[Epub] CrossRef
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment
Y. Wang, Y. Li, L. Xia, K. Niu, X. Chen, D. Lu, R. Kong, Z. Chen, J. Sun
Clinical and Translational Oncology.2018; 20(3): 366. CrossRef
Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
Xin Li, Han Qi, Gou Qing, Ze Song, Lin Xie, Fei Cao, Xiaoming Chen, Weijun Fan
Thoracic Cancer.2018; 9(8): 1012. CrossRef
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
Ming‑Szu Hung, Yu‑Hung Fang, Yu‑Ching Lin, Jr‑Hau Lung, Meng‑Jer Hsieh, Ying‑Huang Tsai
Molecular and Clinical Oncology.2018;[Epub] CrossRef
Risk Factors for Bone Metastasis in Completely Resected Non-Small-Cell Lung Cancer
Hui Wang, Yan Zhang, Hui Zhu, Jinming Yu
Future Oncology.2017; 13(8): 695. CrossRef
Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer
Gino K. In, Jeremy Mason, Sonia Lin, Paul K Newton, Peter Kuhn, Jorge Nieva
Convergent Science Physical Oncology.2017; 3(3): 035002. CrossRef

15,007 View
143 Download
7 Web of Science
8 Crossref

Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis: Yun Hee Lee, Yeon Sil Kim, Sang Nam Lee, Hyo Chun Lee, Se Jin Oh, Seoung Joon Kim, Young Kyoon Kim, Dae Hee Han, Ie Ryung Yoo, Jin Hyung Kang, Suk Hee Hong; Cancer Res Treat. 2015;47(4):676-686. Published online February 13, 2015; DOI: https://doi.org/10.4143/crt.2014.180

Abstract PDF PubReader ePub

Purpose
We examined clinical and dosimetric factors as predictors of symptomatic radiation pneumonitis (RP) in lung cancer patients and evaluated the relationship between interstitial lung changes in the pre-radiotherapy (RT) computed tomography (CT) and symptomatic RP. Materials and Methods Medical records and dose volume histogram data of 60 lung cancer patients from August 2005 to July 2006 were analyzed. All patients were treated with three dimensional (3D) conformal RT of median 56.9 Gy. We assessed the association of symptomatic RP with clinical and dosimetric factors.
Results
With a median follow-up of 15.5 months (range, 6.1 to 40.9 months), Radiation Therapy Oncology Group grade ≥ 2 RP was observed in 14 patients (23.3%). Five patients (8.3%) died from RP. The interstitial changes in the pre-RT chest CT, mean lung dose (MLD), and V30 significantly predicted RP in multivariable analysis (p=0.009, p < 0.001, and p < 0.001, respectively). MLD, V20, V30, and normal tissue complication probability normal tissue complication probability (NTCP) were associated with the RP grade but less so for grade 5 RP. The risk of RP grade ≥ 2, ≥ 3, or ≥ 4 was higher in the patients with interstitial lung change (grade 2, 15.6% to 46.7%, p=0.03; grade 3, 4.4% to 40%, p=0.002; grade 4, 4.4% to 33.3%, p=0.008). Four of the grade 5 RP patients had diffuse interstitial change in pre-RT CT and received chemoradiotherapy. Conclusion Our study identified diffuse interstitial disease as a significant clinical risk for RP, particularly fatal RP. We showed the usefulness of MLD, V20, V30, and NTCP in predicting the incidence and severity of RP.

Citations

Citations to this article as recorded by

Association Between Lung Volume Reduction and Symptomatic Radiation Pneumonitis in Lung Cancer Patients Undergoing Definitive Concurrent Chemoradiotherapy
Jeong Won Lee, Sea-Won Lee, Hyeseon Kang, Yun Hee Lee
Clinical Lung Cancer.2026; 27(3): 98. CrossRef
From dosimetry to deep learning: personalized risk prediction models for radiation pneumonitis
Yi Zhou, Shiting Bai, Yajun Wu, Qian Li, Wei Song, Sisi Chen, Jianglin Chen, Jin Qian, Zhibing Wu, Bingqi Yu
Oncologie.2025; 27(5): 673. CrossRef
Radiation Pneumonitis Risk Assessment Using Fractal Analyses in NSCLC Patients Treated with Curative-Intent Radiotherapy
Jeongeun Hwang, Sun Myung Kim, Joon-Young Moon, Bona Lee, Jeongmin Song, Sookyung Lee, Hakyoung Kim
Life.2025; 15(10): 1596. CrossRef
Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
B. Duchemann, J. Cadranel, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, K. Chouahnia, J. Behr, P.-Y. Brillet, H. Nunes
Revue des Maladies Respiratoires Actualités.2025; 17(2): 2S350. CrossRef
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO)
Paolo Borghetti, Rolando D’Angelillo, Giorgio Facheris, Andrea Borghesi, Alessio Bruni, Paolo Ceruti, Katia Ferrari, Andrea Riccardo Filippi, Sara Ramella, Diego Signorelli, Giovanni Pappagallo, Umberto Ricardi, Serena Badellino, Elisabetta Balestro, Mart
Lung Cancer.2025; 210: 108807. CrossRef
Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia
Shuri Aoki, Hitoshi Ishikawa, Mio Nakajima, Naoyoshi Yamamoto, Shinichiro Mori, Tokuhiko Omatsu, Yuji Tada, Teruaki Mizobuchi, Satoshi Ikeda, Ichiro Yoshino, Shigeru Yamada
Cancers.2024; 16(3): 562. CrossRef
Research Progress of Idiopathic Pulmonary Fibrosis Complicated with Lung Cancer
Hao Ruan, Zihui Zhang, Jiao Tian, Mingjiang Li, Ting Xiao
International Journal of Cancer Management.2024;[Epub] CrossRef
Drug change from nintedanib to pirfenidone for the perioperative management of lung cancer with idiopathic pulmonary fibrosis: A case report
Yukiko Matsui, Mitsuhiro Abe, Yasufumi Uematsu, Yuki Onozato, Takayoshi Yamamoto, Takekazu Iwata
The Journal of the Japanese Association for Chest Surgery.2024; 38(5): 446. CrossRef
Preliminary Results of Developing Imaging Complexity Biomarkers for the Incidence of Severe Radiation Pneumonitis Following Radiotherapy in Non-Small Cell Lung Cancer Patients with Underlying Idiopathic Pulmonary Fibrosis
Jeongeun Hwang, Hakyoung Kim, Sun Myung Kim, Dae Sik Yang
Life.2024; 14(7): 897. CrossRef
CT-based different regions of interest radiomics analysis for acute radiation pneumonitis in patients with locally advanced NSCLC after chemoradiotherapy
Liqiao Hou, Kuifei Chen, Chao Zhou, Xingni Tang, Changhui Yu, Haijian Jia, Qianyi Xu, Suna Zhou, Haihua Yang
Clinical and Translational Radiation Oncology.2024; 48: 100828. CrossRef
Computed tomography patterns and clinical outcomes of radiation pneumonitis in non–small-cell lung cancer patients
Ji Hoon Choi, Hee Kang, Ji Su Lim, Ki-Nam Lee
Acta Radiologica Open.2024;[Epub] CrossRef
Populations particulières : impact de l’état général et des principales comorbidités et de leurs traitements sur la prise en charge thérapeutique locale des patients présentant un Cancer Bronchique Non à Petites Cellules
V. Gounant, R. Ezzedine, B. Duchemann, T. Pierret, S. Brosseau, Y. Castier, G. Zalcman, P. Mordant
Revue des Maladies Respiratoires Actualités.2024; 16(2): 2S290. CrossRef
Development of Imaging Complexity Biomarkers for Prediction of Symptomatic Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer, Focusing on Underlying Lung Disease
Jeongeun Hwang, Hakyoung Kim, Joon-Young Moon, Sun Myung Kim, Dae Sik Yang
Life.2024; 14(11): 1497. CrossRef
Longitudinal microcomputed tomography detects onset and progression of pulmonary fibrosis in conditional Nedd4-2 deficient mice
Dominik H. W. Leitz, Philip Konietzke, Willi L. Wagner, Mara Mertiny, Claudia Benke, Thomas Schneider, Rory E. Morty, Christian Dullin, Wolfram Stiller, Hans-Ulrich Kauczor, Marcus A. Mall, Julia Duerr, Mark O. Wielpütz
American Journal of Physiology-Lung Cellular and Molecular Physiology.2024; 327(6): L917. CrossRef
Hydroalcoholic Sumac Extract as a Protective Agent Against X-Ray-Induced Pulmonary Fibrosis
Faezeh Rezaie, Aboulfazl Ghafouri Khosroshahi, Amir Larki-Harchegani, Alireza Nourian, Hossein Khosravi
Reports of Biochemistry and Molecular Biology.2024; 13(2): 231. CrossRef
Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients
J. Pluvy, A. Zaccariotto, P. Habert, J. Bermudez, A. Mogenet, J.Y. Gaubert, P. Tomasini, L. Padovani, L. Greillier
Respiratory Medicine and Research.2023; 83: 100984. CrossRef
Predictors of high-grade radiation pneumonitis following radiochemotherapy for locally advanced non-small cell lung cancer: analysis of clinical, radiographic and radiotherapy-related factors
Elisabeth Weiss, Anthony Ricco, Nitai Mukhopadhyay, Leila Rezai Gharai, Xiaoyan Deng, Nuzhat Jan, Christopher Guy
Journal of Radiotherapy in Practice.2023;[Epub] CrossRef
Impact of palliative radiotherapy with or without lung irradiation in patients with interstitial lung disease
Kenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, Kei Nagasaki, Yoshifumi Sugawara, Toshiyuki Kozuki
Radiotherapy and Oncology.2023; 183: 109636. CrossRef
Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis – The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging
Nika Guberina, Florian Wirsdörfer, Martin Stuschke, Verena Jendrossek
Neoplasia.2023; 39: 100892. CrossRef
Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease
Maria Azhar, Rodeo Abrencillo, Saumil Gandhi, Mehmet Altan, Ajay Sheshadri
Current Opinion in Pulmonary Medicine.2023; 29(4): 248. CrossRef
Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
B. Duchemann, J. Cadranel, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, O. Freynet, K. Chouanhia, P.Y. Brillet, H. Nunes
Revue des Maladies Respiratoires Actualités.2023; 15(2): 2S214. CrossRef
Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease
Hakyoung Kim, Jeongeun Hwang, Sun Myung Kim, Juwhan Choi, Dae Sik Yang
BMC Cancer.2023;[Epub] CrossRef
Quantification of diffuse parenchymal lung disease in non‐small cell lung cancer patients with definitive concurrent chemoradiation therapy for predicting radiation pneumonitis
Ye Chan An, Jong Hoon Kim, Jae Myung Noh, Kyungmi Yang, You Jin Oh, Sung Goo Park, Hong Ryul Pyo, Ho Yun Lee
Thoracic Cancer.2023; 14(36): 3530. CrossRef
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata
Radiation Oncology.2022;[Epub] CrossRef
Palliative radiotherapy for cancer patients with interstitial lung disease: A physician's perspective
Satoshi Ikeda
Radiotherapy and Oncology.2022; 169: 155. CrossRef
Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review
A. Saha, P. Dickinson, R.K. Shrimali, A. Salem, S. Agarwal
Clinical Oncology.2022; 34(12): e493. CrossRef
Prospective Study of Proton Therapy for Lung Cancer Patients with Poor Lung Function or Pulmonary Fibrosis
Jae Myoung Noh, Hongseok Yoo, Woojin Lee, Hye Yun Park, Sun Hye Shin, Hongryull Pyo
Cancers.2022; 14(6): 1445. CrossRef
Outcomes of proton therapy for non-small cell lung cancer in patients with interstitial pneumonia
Shingo Hashimoto, Hiromitsu Iwata, Yukiko Hattori, Koichiro Nakajima, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Eiko Yamamori, Kenji Akita, Jun-etsu Mizoe, Hiroyuki Ogino, Yuta Shibamoto
Radiation Oncology.2022;[Epub] CrossRef
Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
B. Duchemann, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, O. Freynet, K. Chouahnia, P.-Y. Brillet, H. Nunes
Revue des Maladies Respiratoires Actualités.2022; 14(2): 2S378. CrossRef
Quantitative Assessment and Comparative Analysis of Longitudinal Lung CT Scans of Chest-Irradiated Nonhuman Primates
Priyanka Thakur, John D. Olson, Gregory O Dugan, J. Daniel Bourland, Nancy D. Kock, J. Mark Cline
Radiation Research.2022;[Epub] CrossRef
An Evaluation of Potent Radioprotective Effect of Dimethyl Sulfoxide for Acute Radiation-Induced Lung Injury: Tc99m-DTPA Transalveolar Clearance Scintigraphy Correlated by Histopathologic Findings
Bengu DEPBOYLU
Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi.2022; 9(3): 266. CrossRef
Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Tairo Kashihara, Yuko Nakayama, Kimiteru Ito, Yuko Kubo, Kae Okuma, Satoshi Shima, Satoshi Nakamura, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Yuichiro Ohe, Masahiko Kusumoto, Jun Itami
Advances in Radiation Oncology.2021; 6(1): 100606. CrossRef
Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology
Görkem Türkkan, Yves Willems, Lizza E.L. Hendriks, Rémy Mostard, Lennart Conemans, Hester A Gietema, Cristina Mitea, Stéphanie Peeters, Dirk De Ruysscher
Radiotherapy and Oncology.2021; 155: 269. CrossRef
Radiation-induced lung injury: current evidence
Marisol Arroyo-Hernández, Federico Maldonado, Francisco Lozano-Ruiz, Wendy Muñoz-Montaño, Mónica Nuñez-Baez, Oscar Arrieta
BMC Pulmonary Medicine.2021;[Epub] CrossRef
Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy
Annemarie F. Shepherd, Michelle Iocolano, Jonathan Leeman, Brandon S. Imber, Aaron T. Wild, Michael Offin, Jamie E. Chaft, James Huang, Andreas Rimner, Abraham J. Wu, Daphna Y. Gelblum, Narek Shaverdian, Charles B. Simone, Daniel R. Gomez, Ellen D. Yorke,
Practical Radiation Oncology.2021; 11(1): e52. CrossRef
Scarred Lung. An Update on Radiation-Induced Pulmonary Fibrosis
Natalia Jarzebska, Ekaterina S. Karetnikova, Alexander G. Markov, Michael Kasper, Roman N. Rodionov, Peter M. Spieth
Frontiers in Medicine.2021;[Epub] CrossRef
Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients
Ho Cheol Kim, Seonjeong Lee, Jin Woo Song
Scientific Reports.2021;[Epub] CrossRef
Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy
Fangjuan Li, Hui Liu, Hongyu Wu, Shixiong Liang, Yaping Xu
Radiation Oncology.2021;[Epub] CrossRef
Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease
Masayuki Okumura, Hidehiro Hojo, Masaki Nakamura, Takashi Hiyama, Naoki Nakamura, Sadamoto Zenda, Atsushi Motegi, Yasuhiro Hirano, Shun-Ichiro Kageyama, Raturi Vijay Parshuram, Takeshi Fujisawa, Hirofumi Kuno, Tetsuo Akimoto
Radiotherapy and Oncology.2021; 161: 47. CrossRef
Clinical Outcomes of Pencil Beam Scanning Proton Therapy in Locally Advanced Non-Small Cell Lung Cancer: Propensity Score Analysis
Nalee Kim, Jae Myoung Noh, Woojin Lee, Byoungsuk Park, Hongryull Pyo
Cancers.2021; 13(14): 3497. CrossRef
Survival analysis in lung cancer patients with interstitial lung disease
Hassan Alomaish, Yee Ung, Stella Wang, Pascal N. Tyrrell, Saly Abo Zahra, Anastasia Oikonomou, Claudia Staab-Weijnitz
PLOS ONE.2021; 16(9): e0255375. CrossRef
Fatal Radiation Pneumonitis: Literature Review and Case Series
Stephen Keffer, Christopher L. Guy, Elisabeth Weiss
Advances in Radiation Oncology.2020; 5(2): 238. CrossRef
Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease
Yasuhito Hagiwara, Yuko Nakayama, Shigehiro Kudo, Toyokazu Hayakawa, Naoki Nakamura, Yoshizumi Kitamoto, Shigeo Takahashi, Kayoko Tsujino, Nobuteru Kubo, Yukihisa Tamaki, Yasushi Nagata
Journal of Radiation Research.2020; 61(4): 563. CrossRef
Clinicopathological characteristics of lung cancer in patients with systemic sclerosis
Minjiang Chen, Xiaoyan Liu, Yan Xu, Qing Zhou, Yuequan Shi, Dongming Zhang, Hongge Liang, Jing Zhao, Wei Zhong, Mengzhao Wang
The Clinical Respiratory Journal.2020; 14(12): 1131. CrossRef
Stereotactic Body Radiation Therapy versus Thermal Ablation for Early Stage Non–Small Cell Lung Cancer
Melissa A. L. Vyfhuis, Pranshu Mohindra, Charles B. Simone
Radiology.2019; 290(2): 574. CrossRef
Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy
Hakyoung Kim, Hongryull Pyo, Jae Myoung Noh, Woojin Lee, Byoungsuk Park, Hye Yun Park, Hongseok Yoo
Radiation Oncology.2019;[Epub] CrossRef
Neutrophil‐lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non‐small‐cell lung cancer patients treated with concurrent chemoradiotherapy
Yun Hee Lee, Hoon‐Sik Choi, Hojin Jeong, Ki Mun Kang, Jin Ho Song, Won Sup Lee, Gyeong‐Won Lee, Haa‐Na Song, Hoon‐Gu Kim, Myoung Hee Kang, Dong Yoon Rhee, Bae Kwon Jeong
The Clinical Respiratory Journal.2018; 12(3): 1264. CrossRef
Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)
Daniel Glick, Stephen Lyen, Sonja Kandel, Shane Shapera, Lisa W. Le, Patricia Lindsay, Olive Wong, Andrea Bezjak, Anthony Brade, B.C. John Cho, Andrew Hope, Alexander Sun, Meredith Giuliani
Clinical Lung Cancer.2018; 19(2): e219. CrossRef
The Association Between the Serum KL-6 Level and the Risk of Radiation Pneumonitis
Minehiko Inomata, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toru Yamada, Toshiro Miwa, Kentaro Yamagishi, Kuninori Nomura, Ryuji Hayashi, Kazuyuki Tobe
Haigan.2018; 58(1): 19. CrossRef
Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: evaluation of indications and predictors of decreased respiratory function
Takeaki Ishihara, Kazunari Yamada, Aya Harada, Haruhiro Yukiue, Masayuki Tanahashi, Hiroshi Niwa, Takashi Matsui, Koshi Yokomura, Yasuo Ejima, Ryohei Sasaki
Acta Oncologica.2018; 57(9): 1232. CrossRef
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer
Dwight H. Owen, Lai Wei, Erin M. Bertino, Thomas Edd, Miguel A. Villalona-Calero, Kai He, Peter G. Shields, David P. Carbone, Gregory A. Otterson
Clinical Lung Cancer.2018; 19(6): e893. CrossRef
Managing the oncologic patient with suspected pneumonia in the intensive care unit
D. Leoni, B. Encina, J. Rello
Expert Review of Anti-infective Therapy.2016; 14(10): 943. CrossRef

16,600 View
207 Download
57 Web of Science
52 Crossref

Treatment Outcome of Cisplatin-based Concurrent Chemoradiotherapy in the Patients with Locally Advanced Nasopharyngeal Cancer: Tae Hee Kim, Yoon Ho Ko, Myung Ah Lee, Bum-soo Kim, So Ryoung Chung, Ie Ryung Yoo, Chan-Kwon Jung, Yeon-Sil Kim, Min Sik Kim, Dong-Il Sun, Young Seon Hong, Kyung Shik Lee, Jin-Hyoung Kang; Cancer Res Treat. 2008;40(2):62-70. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.62

Abstract PDF PubReader ePub

Purpose

The standard treatment of locally advanced nasopharyngeal cancer is a concurrent chemoradiotherapy (CCRT), and cisplatin has been used as the most popular chemotherapeutic agent. But many different doses and schedules for cisplatin administration such as daily, weekly and 3 week cycles have been proposed. We compared and analyzed the tumor response, the overall survival, the toxicity and the chemotherapy dose intensity in the patients with locally advanced nasopharyngeal cancer who were treated with CCRT.

Materials and Methods

We performed a retrospective study on 55 patients with locally advanced nasopharyngeal cancer, and they were treated with CCRT as a front-line treatment from Jan 1996 to Jun 2007 at Kangnam Saint Mary's Hospital.

Results

The patients had a median age of 53 years (range: 19~75 years). Of the total 55 patients, a 3-week cycle of 100mg cisplatin was administered in 31 patients and 30 mg weekly cisplatin was administered in 24 patients combined with radiotherapy. Twenty one patients had a complete response and four patients had a partial response for a response rate of 71.4% (95% CI: 59.5~83.3) after CCRT and followed by adjuvant chemotherapy. The complete response rates for the 30 mg and 100 mg cisplatin groups were 72.7% (95% CI: 54.9~90.5) and 54.2% (95% CI: 36.7~71.7), respectively (p=0.23). The duration of CCRT in the 100mg cisplatin group was significantly longer than that of the 30mg cisplatin group (11.1±2.9 weeks vs. 9.0±1.2 weeks, p=0.003). The major deviation group, which was defined as prolongation of the radiotherapy duration for more than 2 weeks, had a significantly lower objective response rate than did the non-deviation group (56.3% vs 84.2%, respectively, p=0.002). The major severe toxicities were leucopenia (49.1%), pharyngoesophagitis (49.1%), anorexia (43.6%), nausea (41.8%) and vomiting (40%).

Conclusions

Weekly 30mg cisplatin-based CCRT is a practical, feasible cisplatin schedule for the patients with locally advanced nasopharyngeal cancer in regard to decreasing the interruption of radiation treatment and decreasing the treatment-related acute toxicities.

Citations

Citations to this article as recorded by

A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study
Jiong-Lin Liang, Yue-Feng Wen, Ying-Ping Huang, Jia Guo, Yun He, Hong-Wei Xing, Ling Guo, Hai-Qiang Mai, Qi Yang
Radiotherapy and Oncology.2025; 203: 110660. CrossRef
The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma
Yi-Jun Hua, Yan-Feng Ou-Yang, Xiong Zou, Le Xia, Dong-Hua Luo, Ming-Yuan Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort
S. Ghosh-Laskar, A. Pilar, K. Prabhash, A. Joshi, J.P. Agarwal, T. Gupta, A. Budrukkar, V. Murthy, M. Swain, V. Noronha, V.M. Patil, P. Pai, D. Nair, D.A. Chaukar, S. Thiagarajan, G. Pantvaidya, A. Deshmukh, P. Chaturvedi, S. Nair, A. D‘Cruz
Clinical Oncology.2019; 31(12): 850. CrossRef
Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study
Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie
Tumor Biology.2016; 37(4): 4429. CrossRef
Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials
Cheng-run Du, Hong-mei Ying, Fang-fang Kong, Rui-ping Zhai, Chao-su Hu
Radiation Oncology.2015;[Epub] CrossRef
Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
Cai-neng Cao, Jing-wei Luo, Li Gao, Jun-lin Yi, Xiao-dong Huang, Kai Wang, Shi-ping Zhang, Yuan Qu, Su-yan Li, Jian-ping Xiao, Zhong Zhang, Guo-zhen Xu, Riccardo Dolcetti
PLOS ONE.2015; 10(3): e0119101. CrossRef
Controversies in the systemic treatment of Nasopharyngeal carcinoma
Herbert H. Loong, Anthony T.C. Chan
Oral Oncology.2014; 50(9): 785. CrossRef
Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma
Junlin Yi, Xiaodong Huang, Li Gao, Jingwei Luo, Shiping Zhang, Kai Wang, Yuan Qu, Jianping Xiao, Guozhen Xu
Radiation Oncology.2014;[Epub] CrossRef
Factors Predict Prolonged Wait Time and Longer Duration of Radiotherapy in Patients with Nasopharyngeal Carcinoma: A Multilevel Analysis
Po-Chun Chen, Ching-Chieh Yang, Cheng-Jung Wu, Wen-Shan Liu, Wei-Lun Huang, Ching-Chih Lee, Bart O. Williams
PLoS ONE.2014; 9(10): e109930. CrossRef
Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area
Weihong Wei, Zeli Huang, Shaoen Li, Hemei Chen, Guoyi Zhang, Shuxia Li, Weihan Hu, Tao Xu
Oncology Research and Treatment.2014; 37(3): 88. CrossRef
Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
Qiu-Yan Chen, Yue-Feng Wen, Ling Guo, Huai Liu, Pei-Yu Huang, Hao-Yuan Mo, Ning-Wei Li, Yan-Qun Xiang, Dong-Hua Luo, Fang Qiu, Rui Sun, Man-Quan Deng, Ming-Yuan Chen, Yi-Jun Hua, Xiang Guo, Ka-Jia Cao, Ming-Huang Hong, Chao-Nan Qian, Hai-Qiang Mai
JNCI: Journal of the National Cancer Institute.2011; 103(23): 1761. CrossRef
Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
Cancer Research and Treatment.2008; 40(4): 155. CrossRef

14,542 View
70 Download
12 Crossref

First
Prev
Page of 1
Next
Last

Search